Vyome Holdings
HINDVyome Holdings is a clinical-stage specialty pharmaceutical company focused on developing next-generation therapeutic solutions for immune-inflammatory and rare diseases.
Earnings
Next report
Nov 13, 2026 (in 3 months)Competitors
By market cap
By revenue growth
Profile
Vyome Holdings is a clinical-stage specialty pharmaceutical company focused on developing next-generation therapeutic solutions for immune-inflammatory and rare diseases. The company leverages a US-India innovation corridor to repurpose existing FDA-approved molecules into novel topical formulations, aiming to reduce drug development costs and timelines. Its core value proposition lies in addressing significant unmet medical needs through a differentiated drug development engine that targets orphan indications with high barriers to entry.
Vyome occupies a niche as a clinical-stage innovator leveraging the US-India corridor to develop orphan drugs for high-unmet-need inflammatory conditions.
FAQ
- What is Vyome Holdings's market cap?
- Vyome Holdings (HIND) has a market capitalization of $15.2M and trades on NASDAQ.
- Who are Vyome Holdings's competitors?
- Vyome Holdings's key competitors include EyePoint Pharmaceuticals, Eli Lilly, Bausch Health, and others. These companies compete in similar markets and product categories.
- Who does Vyome Holdings partner with?
- Vyome Holdings's notable partners include Sun Pharma Laboratories Limited, Eli Lilly and Company, Bausch Health Companies Inc., and others.
- What subsidiaries does Vyome Holdings have?
- Vyome Holdings's subsidiaries include Vyome Therapeutics, Inc., Vyome Therapeutics Limited.
- Where is Vyome Holdings headquartered?
- Vyome Holdings is headquartered in United States of America. It has been publicly traded since 2025.